Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610735 · ClinicalTrials.gov registry record · Phase 1
Combination Therapy for Recurrent Ovarian Cancer
A Phase 1 study of Recurrent Ovarian Cancer, sponsored by Sham Sunder Kakar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05610735 is a Phase 1 study of Recurrent Ovarian Cancer that is actively recruiting participants, run by Sham Sunder Kakar. The registered enrollment target is 72 participants, below the 179-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05610735, a Phase 1 study of Recurrent Ovarian Cancer, is actively recruiting participants, sponsored by Sham Sunder Kakar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study "combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in recurrent ovarian cancer" is focused to determine the feasibility and maximum tolerance dose of Ashwagandha with liposomal doxorubicin (DOXIL) in recurrent ovarian cancer patients. The study contains two parts. In part 1 (phase I), 18 patients with recurrent ovarian cancer eligible for DOXIL therapy will be recruited and three doses of Ashwagandha (2.0 g, 4.0 g and 8.0 g) in the form of tablets along with DOXIL will be evaluated for feasibility and tolerance of ASWD. In part 2 (phase II), 54 patients with recurrent ovarian cancer will be recruited and treated with DOXIL and Ashwagandha (dose determined from part 1) to evaluate the complete response (CR), partial response (PR), and stable disease (SD).
Conditions Studied
Interventions
- DRUG DOXIL
- DRUG Withaferin A
- DRUG Ashwagandha
- DRUG Combination of ASWD and DOXIL
Study Locations (1)
Kentucky
- UofL Health Brown Cancer Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05610735
The ClinicalTrials.gov registry entry for NCT05610735 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (60% lower). The listed sponsor is Sham Sunder Kakar, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Ovarian Cancer appearing as the primary indexed condition, and to 4 interventions - of which DOXIL is the first listed.
NCT05610735 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT05610735 about?
NCT05610735 is a clinical study titled "Combination Therapy for Recurrent Ovarian Cancer". The proposed study "combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in recurrent ovarian cancer" is focused to determine the feasibility and maximum tolerance dose of Ashwagandha with liposomal doxorubicin (DOXIL) in recurrent ovarian cancer patients. The study co...
What is the current status of trial NCT05610735?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-09-25. Estimated completion is 2028-11-30.
What conditions does trial NCT05610735 study?
This clinical trial studies the following conditions: Recurrent Ovarian Cancer.
What interventions are being tested in trial NCT05610735?
The interventions under investigation include: DOXIL (DRUG), Withaferin A (DRUG), Ashwagandha (DRUG), Combination of ASWD and DOXIL (DRUG).
Who is sponsoring clinical trial NCT05610735?
This trial is sponsored by Sham Sunder Kakar, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05610735 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RECRUITING · Phase 1
-
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
RECRUITING · Phase 2
-
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
COMPLETED · Phase 2
-
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.